Macrocyclic Peptides Inhibit HCV NS3 Protease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Hepatitis C virus (HCV) infection, particularly those targeting the NS3 protease, have limited efficacy and are hindered by genetic heterogeneity of the virus, necessitating the development of more effective antiviral compounds.
Innovation Solution
Peptide compounds are designed to inhibit the NS3 protease, either alone or in combination with NS4A, and administered with additional anti-HCV compounds to enhance therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current HCV therapy (alpha-interferon and ribavirin combination) is used, then some viral load reduction is achieved, but sustained efficacy is only achieved in 40% of patients
Solution Approach 1:
The patent changes the chemical structure parameters by introducing macrocyclic constraints and specific substituent patterns (R1, R2, R3, R4, R5, R6 groups) to create protease inhibitors with optimized binding affinity and resistance to viral mutation, thereby improving sustained efficacy while maintaining viral load reduction
Solution Approach 2:
The patent creates composite molecular structures by combining macrocyclic peptide backbones with various functional groups and substituent variations, resulting in a series of compounds with different properties that can address both efficacy and resistance issues simultaneously
2Productivity
If protease inhibitors are developed to improve efficacy, then viral load reduction may be enhanced, but genetic heterogeneity of HCV reduces treatment effectiveness
Solution Approach 1:
The patent designs macrocyclic protease inhibitors with a core structure that maintains consistent binding to the conserved region of the HCV protease across different genotypes, while allowing some flexibility in substituent groups to adapt to genetic variations, achieving universal efficacy against genetically diverse HCV strains
Solution Approach 2:
The patent segments the inhibitor molecule into a rigid macrocyclic core that targets conserved protease regions and flexible substituent groups (R1-R6) that can accommodate genotype variations, allowing the molecule to maintain binding affinity across different HCV genetic backgrounds
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptide compounds effectively inhibit the NS3 protease, offering a potential for improved treatment outcomes for HCV infections by targeting a key viral enzyme, even in the presence of genetic variability.
Implementation Method 1
peptide compounds that can inhibit the functioning of the NS3 protease
Data Source
AI summary
Macrocyclic peptides having the general formula (I): are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.